Fig. 5From: Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrheaRelationship between improvement in chief compliant and global assessment. Improvement in chief compliant that patients had before administration was compared between responders and non-responders for global assessment of relief of overall IBS symptomsBack to article page